About Us
Careers
Partner with us
Forgot password?
Sign in
Login
Login
Email
Password
Forgot your password?
Join VuMedi
Select specialty
Your main specialty
Adult & Family Medicine
Allergy, Asthma, Immunology
Anesthesiology
Cardiovascular
Dental
Dermatology
Emergency Medicine
Endocrinology
Gastroenterology & Hepatology
General Surgery
Hematology & Oncology
Infectious Disease
Medical Genetics
Nephrology
Neurology
Neurosurgery
Obstetrics/Gynecology
Ophthalmology
Oral Maxillofacial
Orthopaedics
Otolaryngology
Pathology
Pediatrics
Physical Medicine & Rehab
Plastic Surgery
Podiatry
Preventive Medicine
Psychiatry
Pulmonology
Radiation Oncology
Radiology
Rheumatology
Urology
First name
Last name
Email
Choose Password
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
https://www.soho2019.com/
Hodgkin Lymphoma
Multiple Myeloma
Chronic Lymphocytic Leukemia
Meet The Professor Sessions
Chronic Myeloid Leukemia
Myeloproliferative Neoplasms
Breakfast With The Expert
Independent Satellite Symposium
Plenary Sessions
Evolving Practices in AML: A Case-based Guide to New and Emerging Treatment Options
Acute Lymphoblastic Leukemia
Myelodysplastic Syndromes
Acute Myeloid Leukemia
Indolent B-cell Lymphoma
Mantle Cell Lymphoma
Aggressive B-cell Lymphoma
T-cell Lymphoma
Cellular Therapy
Next Questions
Events
Playback speed
0.5x
0.75x
1x (Normal)
1.25x
1.5x
1.75x
2x
10 seconds
Induction Therapy for Myeloma in 2019 and Beyond: Is MRD Our Goal and How Do We Get There - Is RVD Good Enough?
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Amrita Krishnan
By
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
FEATURING
Amrita Krishnan
139 views
October 17, 2019
0 Comments
Login to view comments.
Click here to Login
Featured Video
15:14
Icahn School of Medicine at Mount Sinai
Safety Profile of Ruxolitinib in Patients With MF
Feat.
D. Tremblay
Featured Video
06:51
Insights from 2023 ASH Annual Meeting
ASH 2023 Insights: "Prevalence and Prediction of Ruxolitinib Tr…
Feat.
D. Tremblay
Meet The Professor Sessions
15:59
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
New Kinase Inhibitors for CML: Asciminib, PF-114, & HQP1351
Feat.
M. Mauro
18:04
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Biomarkers To Predict Treatment Free Remission in CML – Can We Predi…
Feat.
T. Hughes
19:12
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Management of Advanced Phase CML: Treatment Options for Accelerated…
Feat.
E. Jabbour
14:57
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Where do Immunotherapies Fit in the Treatment Landscape of ALL?
Feat.
P. Kebriaei
14:33
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
How To Cure The Very High Risk Childhood ALL? Dasatinib vs. Imatinib…
Feat.
C. Pui
15:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
The Future of Frontline ALL in Adults: Complex Biological Work up an…
Feat.
N. Boissel
14:54
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Harnessing the Immune System for Treating AML: Targeting CD33 and IL…
Feat.
F. Ravandi
15:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
IDH Inhibitor Therapy in AML: Ivosidenib & Enasidenib Mono and C…
Feat.
C. DiNardo
10:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Manipulating Microenvironment to Overcome Chemotherapy Resistance in…
Feat.
D. DeAngelo
22:31
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Identification and Management of Patients with Polycythemia Vera and…
Feat.
S. Verstovsek
15:43
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Combination Approaches With Ruxolitinib in Primary Myelofibrosis - W…
Feat.
N. Pemmaraju
13:07
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Identification and Management of Ruxolitinib Failure in Myelofibrosi…
Feat.
L. Masarova
10:24
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Double-Hit Lymphoma Diagnosis, Initial and Relapsed/Refractory Treat…
Feat.
K. Dunleavy
13:26
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
The Role of Venetoclax in DLBCL: Efficacy and Safety Results from th…
Feat.
A. Zelenetz
11:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Treating Elderly Patients with Hodgkin Lymphoma - How Much Bleomycin…
Feat.
A. Moskowitz
31:49
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
From CHIP, ICUS, and CCUS to Myelodysplastic Syndromes: Disease Stat…
Feat.
L. Godley
20:22
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Lower Risk Myelodysplastic Syndromes Management: Overview of the Cur…
Feat.
R. Komrokji
25:15
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Higher Risk Myelodysplastic Syndromes Management: Overview of the C…
Feat.
V. Santini
09:54
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Induction Therapy for Myeloma in 2019 and Beyond: Is MRD Our Goal an…
Feat.
A. Krishnan
12:16
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Discrepancy Between Real World vs. Clinical Trial Data in Relapsed/R…
Feat.
M. Dimopoulos
17:13
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Epigenetic Mechanisms in CLL: Inter- and Intra-Patient Heterogeneity…
Feat.
D. Rossi
19:03
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Mechanisms of Resistance in CLL to Targeted Agents: Could We Use The…
Feat.
P. Ghia
18:11
Society of Hematologic Oncology Seventh Annual Meeting (SOHO 2019)
Genomic Complexity of CLL: Complex Karyotype, Cytogenetic Complexity…
Feat.
R. Brandell
